Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus‐infected children in relation to treatment outcomes
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13998
Abstract: Describe the pharmacokinetics (PK) of the antiretroviral drugs abacavir and lamivudine in malnourished paediatric patients and relate to viral load outcomes after 12 and 48 weeks of treatment. read more here.
Keywords: severely malnourished; treatment; population pharmacokinetics; pharmacokinetics abacavir ... See more keywords
Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
Sign Up to like & getrecommendations! Published in 2020 at "AIDS Research and Therapy"
DOI: 10.1186/s12981-020-00272-5
Abstract: Background The anti-retroviral combination of abacavir/lamivudine plus rilpivirine (ABC/3TC/RPV) is not recommended by international guidelines as the first-line regimen. However, it is potent, well-tolerated, and affordable, especially in resource-limited settings. This study evaluates the efficacy and… read more here.
Keywords: treatment; treatment hiv; group; abacavir lamivudine ... See more keywords
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286)
Sign Up to like & getrecommendations! Published in 2022 at "Patient preference and adherence"
DOI: 10.2147/ppa.s379065
Abstract: Background Many people living with HIV struggle to consistently adhere to antiretroviral therapy, fail to achieve long-term virologic control and remain at risk for HIV-related disease progression, development of resistance and may transmit HIV infection… read more here.
Keywords: adherence support; adherence; living hiv; people living ... See more keywords